Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Big Pharma Explores New Frontier Of Lung Cancer Immunotherapy

Executive Summary

Lung cancer wasn’t viewed traditionally as a tumor that would respond to immunotherapy. But with checkpoint inhibitor data looking promising, big pharma is diving in and prioritizing the disease, reeled in by the large patient population and high unmet need.

You may also be interested in...

Latest PD-L1 Lung Cancer Data Increases Debate On Biomarker

Data and filing announcements for Bristol and Merck’s PD-1 inhibitors in lung cancer put PD-L1 inhibitor developers in hot seat and create more debate about strategy and practicality of the PD-L1 biomarker.

Industry, Cancer Groups Draft Blueprint For PD-1 Companion Dx Approvals

Drug and test firms want to standardize FDA's companion diagnostic assessments for the high-profile new class of PD-1/PD-LI immunotherapy cancer drugs, an issue discussed at a recent FDA/cancer groups meeting.

Opdivo Lung Cancer Approval Holds Lessons For Competitors

Bristol is required to run a new study assessing the risk for pneumonitis, but analysts do not see the adverse event as a competitive threat. FDA showed significant flexibility with broad, fast approval, but Opdivo’s survival advantage may raise the bar for the rest of the class.

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts